Pioneering The Development of Novel Therapeutics Targeting Stress Support Pathways

Ribon is a clinical stage biopharmaceutical company pursuing the development of novel small molecules targeting stress support pathways in cancer and inflammation using our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform.

Learn More

Our Proprietary BEACON+ Platform

We have created our proprietary BEACON+ to unlock the biochemical roles of NAD+-utilizing enzymes and to discover and develop novel small molecule therapeutics.

Learn More

RBN-2397 – PARP7 Inhibitor

Developing our lead product candidate, RBN-2397, as a potent, selective and orally available small molecule inhibitor of the monoPARP, PARP7, for the treatment of solid tumors.

Learn More
April 11

Cambridge, MA

Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting

Learn More
Join our team of experts.
Find Out More